← back to search

Marye J. Boers‐Sonderen

Radboud University Nijmegen · NL
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, and CAR-T cell therapy research.
h-index
23
citations
2,307
works
124
NIH funding
primary concept
Medicine
email

Recent publications

A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors
Clinical Cancer Research 2025cited by 8position: middledoi
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
European Journal of Cancer 2024cited by 51position: middledoi
Long-Term Survival in Patients With Advanced Melanoma
JAMA Network Open 2024cited by 34position: middledoi
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
EClinicalMedicine 2024cited by 22position: middledoi
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma
European Journal of Cancer 2024cited by 16position: middledoi
BRAF/MEK inhibitor rechallenge in advanced melanoma patients
Cancer 2024cited by 14position: middledoi
Adjuvant treatment with anti‐ <scp>PD</scp> ‐1 in acral melanoma: A nationwide study
International Journal of Cancer 2024cited by 11position: middledoi
Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Cancer Research 2023cited by 13position: middledoi
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
New England Journal of Medicine 2022cited by 516position: middledoi
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma
NEJM Evidence 2022cited by 145position: middledoi
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma
JAMA Oncology 2022cited by 104position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Geke A.P. Hospers · University Medical Center Groningen6 papers (2022–2024)Willeke A.M. Blokx · Utrecht University6 papers (2022–2024)Djura Piersma · Medisch Spectrum Twente6 papers (2022–2024)Ellen Kapiteijn · University of Amsterdam6 papers (2022–2024)Karijn P.M. Suijkerbuijk · Utrecht University6 papers (2022–2024)Astrid A.M. van der Veldt · Erasmus MC5 papers (2022–2024)John B.A.G. Haanen · Nikki-Universal (Japan)5 papers (2022–2024)Olivier J. van Not · Utrecht University5 papers (2022–2024)Christian U. Blank · Dutch Cancer Society5 papers (2022–2024)Franchette W.P.J. van den Berkmortel · Zuyderland Medisch Centrum5 papers (2022–2024)Jan Willem B. de Groot · Isala4 papers (2022–2024)Gerard Vreugdenhil · Association of British Orchestras4 papers (2022–2024)Michel W.J.M. Wouters · Northwestern University4 papers (2024–2024)Rozemarijn S. van Rijn · Medisch Centrum Leeuwarden4 papers (2024–2024)Alfons J.M. van den Eertwegh · Amsterdam Neuroscience4 papers (2024–2024) · 3 papers (2022–2024) · 3 papers (2022–2024)Marion A. M. Stevense‐den Boer · Amphia Ziekenhuis2 papers (2024–2024)Rik J. Verheijden · Utrecht University2 papers (2022–2024) · 2 papers (2024–2024)